Adam Schayowitz, the Executive Vice President and Head of Research and Development at Zymeworks Inc., has reported significant transactions concerning his stock ownership. According to a recent SEC filing, Schayowitz acquired and disposed of shares of Zymeworks common stock on October 9, 2026. This event is noteworthy as it underscores the ongoing trends in executive stock transactions within the pharmaceutical industry.
Background
Zymeworks Inc. is a company based in Middletown, Delaware, primarily engaged in the development of innovative therapies in the life sciences sector. The company is classified under the SIC code for Pharmaceutical Preparations. Recent filings indicate that Zymeworks has been active in the market, with various forms submitted to the SEC, including Form 4 and Form 144, reflecting ongoing corporate activities.
What the Filing Says
The SEC filing reveals that Schayowitz executed two transactions on October 9, 2026. He acquired 37,037 shares of common stock, which were issued upon the vesting of restricted stock units granted on October 9, 2025. Additionally, he sold 13,832 shares at a weighted average price of $25.85 to cover tax withholding obligations related to the vesting of these units. Following these transactions, Schayowitz now holds a total of 74,074 shares in Zymeworks.
Impact
This update may affect Zymeworks' stakeholders, including investors and employees, as it reflects the company's approach to executive compensation and stock management. The transactions highlight the importance of compliance with SEC regulations regarding insider trading and executive disclosures. Moreover, it may influence perceptions of the company's financial health and governance practices.
What's Next
The filing does not say what happens next.